Date: October 23, 2023

To: SMA PAGs
From: Patient Advocacy at Biogen
Subject: Biogen Update on DEVOTE and RESPOND Clinical Trial Recruitment

Dear SMA Community,

We are pleased to share that we recently completed enrollment of the global DEVOTE and RESPOND studies. While these studies are still ongoing, they are no longer recruiting new participants. DEVOTE and RESPOND are part of our broader research plan to better understand the safety and potential benefits of SPINRAZA® (nusinersen) for spinal muscular atrophy (SMA) in a multi-treatment landscape:

- DEVOTE is a Phase 2/3 study investigating the safety, tolerability, and efficacy of investigational higher dose nusinersen* in individuals of all ages with SMA.
- RESPOND is a Phase 4 open-label study to evaluate clinical outcomes and safety following treatment with SPINRAZA in infants and toddlers with SMA who have unmet clinical needs after treatment with onasemnogene abeparvovec.

More details about DEVOTE and RESPOND are included below.

Biogen aims to help people with SMA and their loved ones by continuing to pursue the science around treatment effects and advancing research in areas of unmet medical need. We are profoundly grateful to the patients, caregivers, and investigators currently involved in the DEVOTE and RESPOND studies and recognize their significant contributions to SMA research. We will continue to try to answer critical questions for the SMA community through our ongoing efforts.

About DEVOTE

- DEVOTE is a complex, three-part study evaluating investigational higher dose nusinersen.
- Biogen presented safety data from Part A at the 2022 SMA Research & Clinical Care Meeting hosted by Cure SMA.
- Part B of the DEVOTE study is a pivotal, double-blind, active control randomized treatment cohort that will inform on the effectiveness and safety of the investigational dose of nusinersen. Neither Biogen nor the study investigators know which study participants are receiving the investigational dose and which participants are receiving the approved dose of nusinersen. Participants will be followed for one year.

- Note, while Biogen was greatly encouraged by the early safety data shared, the DEVOTE trial remains ongoing and the overall safety and efficacy of higher dose nusinersen as a treatment for SMA has not yet been established.

About RESPOND

- As an open label study, RESPOND will continue to generate data over the two-year study period.
- Biogen has presented baseline characteristics and safety data as well as initial clinical outcomes data from the study at recent medical congresses.

*Nusinersen is currently commercialized under the brand name SPINRAZA® and the U.S. Food and Drug Administration-approved dose is 12 mg.

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Click here to access full Prescribing Information.

This information is not intended to replace discussions with your healthcare provider.

Sincerely,
Your Team at Biogen